. 2020 Oct;8(19):1225. doi: 10.21037/atm-20-4544

Table 7. Detection of BRAF^V600E mutation in three types of samples from PTC patients.

Sample	cfDNA			FFPE			gDNA
Sample	Coverage	VarReads	VarFreq	Coverage	VarReads	VarFreq	Coverage	VarReads	VarFreq
2	6,187	0	0	1,117	252	22.56%	490	0	0
3	4,759	0	0	546	118	21.61%	828	0	0
5	1,651	0	0	618	70	11.33%	906	0	0
6	2,299	0	0	538	151	28.07%	771	0	0
7	1,497	0	0	806	205	25.43%	787	0	0
8	4,841	0	0	122	22	18.03%	664	0	0
9	3,900	0	0	407	49	12.04%	497	0	0
10	1,572	0	0	571	26	4.55%	857	0	0

BRAF^V600E mutations were not detected in 3 types of samples in patient 1 and 4. PTC, papillary thyroid carcinoma; cfDNA, cell-free DNA; FFPE, formalin-fixed and paraffin-embedded.

Table 7. Detection of BRAFV600E mutation in three types of samples from PTC patients.

Table 7. Detection of BRAF^V600E mutation in three types of samples from PTC patients.